All material subject to strictly enforced copyright laws. © 2021 Euromoney Institutional Investor PLC group
EquityABBs-Block Trades

Healthcare ECM still intact despite Nasdaq correction

Oncopeptides_Biotech_PA_575_375

Swedish pharmaceutical company Oncopeptides has placed Skr1.1bn ($132m) of new shares to finance the commercialisation of its lead product candidate in the United States, and the development of other treatments.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree